DDInter1544 DDInter994
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. This drug was first approved in Japan on 25 March 2013. Istradefylline was granted FDA approval on 27 August 2019.
Istradefylline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Istradefylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Istradefylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Istradefylline {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Istradefylline {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Istradefylline may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Istradefylline may lead to a major life threatening interaction when taken with Apalutamide
Istradefylline may lead to a major life threatening interaction when taken with Idelalisib